Enterprise AI Analysis
Machine Learning-Based Assessment of the Healthy Human Gut Mycobiota Landscape using ITS1 DNA Metabarcoding Data
This study presents an advanced framework combining DNA metabarcoding with Machine Learning (ML) and Explainable AI (XAI) to map the healthy human gut mycobiome. By analyzing ~1,500 public datasets, our AI models achieve over 80% accuracy in predicting host health, identifying key fungal genera as diagnostic biomarkers. This represents a significant leap towards non-invasive health diagnostics.
0%
Prediction Accuracy
0
Datasets Analyzed
0
Key Fungal Biomarkers
Executive Impact: Revolutionizing Gut Health Diagnostics
The Challenge
The human gut mycobiome remains largely unexplored compared to bacteria.
Defining a "healthy" mycobiome is elusive, hindering robust diagnostic marker identification.
Traditional metabarcoding faces challenges with ITS1 length variability and batch effects in diverse datasets.
Incomplete metadata in public repositories limits comprehensive correlational analyses.
The AI Solution
Integrated AI Framework: Combines advanced DNA metabarcoding, Machine Learning (Random Forest), and Explainable AI (SHAP) for a multiview analysis.
Enhanced Data Processing: Utilizes BioMaS to handle ITS1 length variability, processing both merged and unmerged reads effectively.
Predictive Biomarker Discovery: Identified key fungal genera (*Eurotium, Aureobasidium, Candida, Cutaneotrichosporon*) as strong predictive markers for health status.
Robust Classification: Achieved up to 87% accuracy in discriminating healthy vs. non-healthy individuals.
Quantified Impact
Diagnostic Precision Achieved
87%
Public Data Capitalized
~1,500
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
Understanding the Gut Mycobiome
The human gut microbiome is critical for host health, yet its fungal component, the mycobiome, remains largely underexplored. This study addresses this gap by presenting a comprehensive analysis of fungal communities in healthy and non-healthy individuals, highlighting its significant role from birth and its influence by factors like diet and environment.
Previous research primarily focused on prokaryotic microbiomes, leaving the fungal counterpart as a "dark matter" in gut health. Understanding the mycobiome is crucial as it influences host immunity, metabolism, and can be implicated in various chronic diseases, including cancer and obesity.
Cutting-Edge Multiview Analytical Framework
This study employs a robust methodology that combines DNA metabarcoding with advanced Machine Learning (ML) and Explainable Artificial Intelligence (XAI) techniques. Raw sequencing data from ~1,500 public ITS1 datasets were retrieved and processed using the BioMaS pipeline, integrated with ITSoneWB and ITSoneDB for taxonomic classification.
The analytical pipeline included rigorous steps: quality control, read merging (BioMaS handles ITS1 length variability by processing both merged and unmerged reads), alignment, taxonomic assignment via TANGO, and contaminant filtering using the WoRMS database. Alpha and beta diversity analyses were performed, followed by differential abundance analysis using LEfSe and Maaslin2. Crucially, Random Forest (RF) models were trained for classification, with feature importance assessed using SHAP values, providing transparent insights into model predictions.
Key Findings: Predictive Power and Biomarkers
The ML models achieved high predictive performance, with accuracies exceeding 80% and reaching up to 87% for host health status prediction. Fungal genera such as Eurotium, Aureobasidium, Candida, and Cutaneotrichosporon were identified as key classification features, with specific associations to healthy or non-healthy states. For instance, Eurotium and Aureobasidium were more abundant in healthy individuals, while Candida and Cutaneotrichosporon were associated with non-healthy conditions.
Interestingly, including age as a covariate further improved model accuracy. Alpha diversity analyses showed marginal trends, suggesting limited discriminatory power of fungal richness alone, while beta diversity revealed BioProject-specific technical factors as the dominant source of variance, emphasizing the importance of robust analytical approaches to handle batch effects.
Implications and Future Directions
This study validates ITS1 DNA metabarcoding coupled with ML/XAI as a powerful tool for analyzing gut mycobiome data and distinguishing health statuses. The identification of specific fungal genera as biomarkers opens new avenues for non-invasive diagnostics and targeted therapeutic interventions.
Despite the success, the study underscores limitations arising from incomplete metadata in public repositories (e.g., BMI, diet, lifestyle), which could introduce biases. Future research should focus on larger, more diverse cohorts, integrating multi-omics data (metabolomics, proteomics), and ensuring FAIR-compliant data sharing to enhance generalizability and robustness of findings.
Enterprise Process Flow: ML-based Mycobiota Assessment
Public Data Retrieval
→
DNA Metabarcoding (ITSoneWB, BioMaS)
→
Taxonomic Assignments (TANGO)
→
Contaminant Filtering
→
Diversity Analysis (Alpha/Beta)
→
Co-occurrence Networks (NetCoMi)
→
Machine Learning (RF, XAI)
87%
Peak Machine Learning Accuracy for Host Health Status Prediction
| Key Fungal Genera for Health Status Classification | Healthy-Associated | Non-Healthy-Associated |
|---|---|---|
| Biomarker Presence |
|
|
Leveraging Public Repositories: The FAIR Data Principle
This study utilized approximately 1,500 publicly available ITS1 datasets, demonstrating the power of data reuse for comprehensive analyses. This approach significantly expands the scope beyond single-cohort studies, offering broader generalizability to the healthy human gut mycobiota landscape.
However, the study also highlighted limitations due to incomplete technical and biological metadata in public repositories, such as BMI, diet, and smoking habits. This variability can impact compositional analyses and hinder direct comparisons across diverse cohorts.
The findings underscore a critical need for consistent, comprehensive, and FAIR-compliant (Findability, Accessibility, Interoperability, Reusability) sharing of both raw data and rich metadata. Adopting these principles will enhance the reproducibility and impact of future microbiome research and accelerate biomarker discovery.
Calculate Your Potential AI Impact
Estimate the operational efficiencies and cost savings AI could bring to your organization by optimizing data analysis workflows and diagnostic capabilities.
Annual AI-Driven Impact
Estimated Cost Savings
Productive Hours Reclaimed
Your AI Implementation Roadmap
A typical timeline for integrating advanced AI solutions for precision diagnostics and research, tailored to your enterprise needs.
Phase 01: Discovery & Strategy (2-4 Weeks)
Comprehensive assessment of existing data infrastructure, research objectives, and diagnostic workflows. Development of a tailored AI strategy and platform architecture design.
Phase 02: Data Integration & Model Training (8-12 Weeks)
Secure integration of diverse biological datasets, data cleaning, and feature engineering. Development and training of custom machine learning models, including explainable AI components.
Phase 03: Validation & Deployment (4-6 Weeks)
Rigorous internal and external validation of AI models against benchmark datasets. Seamless deployment of the AI system into your existing research or clinical diagnostic pipeline.
Phase 04: Continuous Optimization & Support (Ongoing)
Post-deployment monitoring, performance tuning, and iterative model improvements. Ongoing technical support and updates to ensure sustained high performance and adaptability.
Unlock the Future of Precision Diagnostics
Ready to transform your gut health research and diagnostic capabilities with cutting-edge AI? Our experts are here to guide you.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat